S-1 Filing

GUIDED THERAPEUTICS INC CIK: 924515

Filing Information

Form Type	S-1
Accession Number	`0001121781-15-000085`
Period End Date	20141231
Filing Date	20150423
Fiscal Year	N/A
Fiscal Period	N/A
XBRL Instance	gthp-20141231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 81 Income Statement 44 Cash Flow Statement 71 Stockholders Equity 18

Balance Sheet 81 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$76.00K	USD	Point-in-time
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$18.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$613.00K	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$144.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$162.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.04M	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$184.00K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $76 and $18 at December 31, 2014 and 2013, respectively	`AccountsReceivableNet`	$338.00K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $76 and $18 at December 31, 2014 and 2013, respectively	`AccountsReceivableNet`	$133.00K	USD	Point-in-time
Series B convertible preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Inventory, net of reserves of $144 and $184 at December 31, 2014 and 2013, respectively	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$1.18M	USD	Point-in-time
Series B convertible preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Inventory, net of reserves of $144 and $184 at December 31, 2014 and 2013, respectively	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$1.19M	USD	Point-in-time
Series B convertible preferred stock, authorized	`PreferredStockSharesAuthorized`	3.00	shares	Point-in-time
Series B convertible preferred stock, authorized	`PreferredStockSharesAuthorized`	3.00	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$99.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$101.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.78M	USD	Point-in-time
Series B convertible preferred stock, issued	`PreferredStockSharesIssued`	1.20	shares	Point-in-time
Total current assets	`AssetsCurrent`	$2.04M	USD	Point-in-time
Series B convertible preferred stock, issued	`PreferredStockSharesIssued`	2.10	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$587.00K	USD	Point-in-time
Series B convertible preferred stock, outstanding	`PreferredStockSharesOutstanding`	2.10	shares	Point-in-time
Series B convertible preferred stock, outstanding	`PreferredStockSharesOutstanding`	1.20	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$920.00K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$101.00K	USD	Point-in-time
Other assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$356.00K	USD	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	145,000.00	shares	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	195,000.00	shares	Point-in-time
Debt Issue Cost	`UnamortizedDebtIssuanceExpense`	$564.00K	USD	Point-in-time
Debt Issue Cost	`UnamortizedDebtIssuanceExpense`	-	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$1.25M	USD	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	96,889.00	shares	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$1.28M	USD	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	70,479.00	shares	Point-in-time
TOTAL ASSETS	`Assets`	$3.03M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$3.32M	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	96,889.00	shares	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	70,479.00	shares	Point-in-time
Short-term notes payable	`ShorttermNotesPayable`	$35.00K	USD	Point-in-time
Short-term notes payable	`ShorttermNotesPayable`	$646.00K	USD	Point-in-time
Current portion of long-term debt	`ShortTermBorrowings`	$123.00K	USD	Point-in-time
Current portion of long-term debt	`ShortTermBorrowings`	$109.00K	USD	Point-in-time
Short-term notes payable, net of discount	`NotesPayableCurrent`	-	USD	Point-in-time
Short-term notes payable, net of discount	`NotesPayableCurrent`	$1.06M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.73M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$891.00K	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$1.01M	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$723.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$14.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$24.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.60M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.77M	USD	Point-in-time
Warrants, at fair value	`WarrantsNotSettleableInCashFairValueDisclosure`	$2.07M	USD	Point-in-time
Warrants, at fair value	`WarrantsNotSettleableInCashFairValueDisclosure`	$1.55M	USD	Point-in-time
Long-term debt, net	`LongtermDebtPayableLessCurrentPortion`	$40.00K	USD	Point-in-time
Long-term debt, net	`LongtermDebtPayableLessCurrentPortion`	$103.00K	USD	Point-in-time
Convertible note, net of discount	`ConvertibleLongTermNotesPayable`	$783.00K	USD	Point-in-time
Convertible note, net of discount	`ConvertibleLongTermNotesPayable`	-	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$2.89M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$1.65M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$3.42M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$7.50M	USD	Point-in-time
Series B convertible preferred stock, $.001 par value; 3 shares authorized, 1.2 and 2.1 shares issued and outstanding as of December 31, 2014 and 2013, respectively (liquidation preference of $1,200 and $2,100 at December 31, 2014 and 2013, respectively)	`ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue`	$678.00K	USD	Point-in-time
Series B convertible preferred stock, $.001 par value; 3 shares authorized, 1.2 and 2.1 shares issued and outstanding as of December 31, 2014 and 2013, respectively (liquidation preference of $1,200 and $2,100 at December 31, 2014 and 2013, respectively)	`ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue`	$1.14M	USD	Point-in-time
Common stock, $.001 par value; 195,000 and 145,000 shares authorized, 96,889 and 70,479 shares issued and outstanding as of December 31, 2014 and 2013, respectively	`CommonStockValue`	$71.00K	USD	Point-in-time
Common stock, $.001 par value; 195,000 and 145,000 shares authorized, 96,889 and 70,479 shares issued and outstanding as of December 31, 2014 and 2013, respectively	`CommonStockValue`	$97.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$107.95M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$101.84M	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$132.00K	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$132.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-113.06M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-103.03M	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	`TotalGuidedTherapeuticsStockholdersEquity`	$-4.46M	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	`TotalGuidedTherapeuticsStockholdersEquity`	$-107.00K	USD	Point-in-time
TOTAL STOCKHOLDERS (DEFICIT) EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-4.46M	USD	Point-in-time
TOTAL STOCKHOLDERS (DEFICIT) EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-107.00K	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$3.03M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$3.32M	USD	Point-in-time

Income Statement 44 line items

Line Item	Tag	Value	Unit	Period
Sales - devices and disposables	`SalesDevicesAndDisposables`	$359.00K	USD	Annual
Sales - devices and disposables	`SalesDevicesAndDisposables`	$758.00K	USD	Annual
Cost of goods sold	`CostOfGoodsSold`	$891.00K	USD	Annual
Cost of goods sold	`CostOfGoodsSold`	$611.00K	USD	Annual
Gross Loss	`GrossProfit`	$-252.00K	USD	Annual
Gross Loss	`GrossProfit`	$-133.00K	USD	Annual
Contract and grant revenue	`Revenues`	$820.00K	USD	Annual
Contract and grant revenue	`Revenues`	$65.00K	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.79M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.74M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$901.00K	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$1.16M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.65M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.53M	USD	Annual
Total operating expenses	`OperatingExpenses`	$8.60M	USD	Annual
Total operating expenses	`OperatingExpenses`	$7.17M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-8.67M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-6.61M	USD	Annual
Other income	`OtherIncome`	$25.00K	USD	Annual
Other income	`OtherIncome`	$110.00K	USD	Annual
Interest expense	`InterestExpense`	$45.00K	USD	Annual
Interest expense	`InterestExpense`	$979.00K	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-325.00K	USD	Annual
Change in fair value of warrants	`DerivativeGainLossOnDerivativeNet`	$65.00K	USD	Annual
Change in fair value of warrants	`DerivativeGainLossOnDerivativeNet`	$-674.00K	USD	Annual
Total other income	`TotalOtherIncome`	$-1.21M	USD	Annual
Total other income	`TotalOtherIncome`	$-609.00K	USD	Annual
LOSS FROM OPERATIONS	`LossBeforeIncomeTaxes`	$9.88M	USD	Annual
LOSS FROM OPERATIONS	`LossBeforeIncomeTaxes`	$7.21M	USD	Annual
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	Annual
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	Annual
NET LOSS	`NetIncomeLoss`	$-7.21M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-9.88M	USD	Annual
DEEMED DIVIDENDS	`InvestmentIncomeDividend`	$-3.17M	USD	Annual
DEEMED DIVIDENDS	`InvestmentIncomeDividend`	-	USD	Annual
PREFERRED STOCK DIVIDENDS	`PreferredStockDividendsIncomeStatementImpact`	-	USD	Annual
PREFERRED STOCK DIVIDENDS	`PreferredStockDividendsIncomeStatementImpact`	$-152.00K	USD	Annual
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-10.04M	USD	Annual
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-10.39M	USD	Annual
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	`EarningsPerShareBasicAndDiluted`	$-0.16	USD	Annual
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	`EarningsPerShareBasicAndDiluted`	$-0.13	USD	Annual
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	65,884.00	shares	Annual
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	77,061.00	shares	Annual

Cash Flow Statement 71 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-7.21M	USD	Annual
Net loss	`NetIncomeLoss`	$-9.88M	USD	Annual
Bad debt expense	`BadDebtRecovery`	$63.00K	USD	Annual
Bad debt expense	`BadDebtRecovery`	$7.00K	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-325.00K	USD	Annual
Depreciation	`DepreciationAndAmortization`	$483.00K	USD	Annual
Depreciation	`DepreciationAndAmortization`	$461.00K	USD	Annual
Amortization	`AdjustmentForAmortization`	$757.00K	USD	Annual
Amortization	`AdjustmentForAmortization`	-	USD	Annual
Stock based compensation	`ShareBasedCompensation`	$886.00K	USD	Annual
Stock based compensation	`ShareBasedCompensation`	$824.00K	USD	Annual
Change in fair value of warrants	`ChangeInFairValueOfWarrants`	$-65.00K	USD	Annual
Change in fair value of warrants	`ChangeInFairValueOfWarrants`	$674.00K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$267.00K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$33.00K	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$669.00K	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$-14.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-2.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-97.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$25.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-254.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$126.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$842.00K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$10.00K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-26.00K	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$223.00K	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$296.00K	USD	Annual
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$3.60M	USD	Annual
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$1.66M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-5.56M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-6.28M	USD	Annual
Additions to fixed assets	`AdditionsToFixedAssets`	$-150.00K	USD	Annual
Additions to fixed assets	`AdditionsToFixedAssets`	$-107.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-150.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-107.00K	USD	Annual
Net proceeds from issuance of common stock and warrants, net	`ProceedsFromIssuanceOfCommonStock`	$1.73M	USD	Annual
Net proceeds from issuance of common stock and warrants, net	`ProceedsFromIssuanceOfCommonStock`	$2.21M	USD	Annual
Proceeds from debt financing, net of discount	`ProceedsFromIssuanceOfDebt`	$5.26M	USD	Annual
Proceeds from debt financing, net of discount	`ProceedsFromIssuanceOfDebt`	$115.00K	USD	Annual
Loan acquisition costs	`AmortizationOfFinancingCostsAndDiscounts`	$-452.00K	USD	Annual
Loan acquisition costs	`AmortizationOfFinancingCostsAndDiscounts`	-	USD	Annual
Payments on notes payables	`PaymentsOfLoanCosts`	$374.00K	USD	Annual
Payments on notes payables	`PaymentsOfLoanCosts`	$656.00K	USD	Annual
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$97.00K	USD	Annual
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$3.28M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.23M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.98M	USD	Annual
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-451.00K	USD	Annual
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-432.00K	USD	Annual
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$613.00K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$162.00K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$1.04M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of year	`Cash`	$162.00K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of year	`Cash`	$613.00K	USD	Point-in-time
Cash paid for Interest	`InterestPaid`	$33.00K	USD	Annual
Cash paid for Interest	`InterestPaid`	$31.00K	USD	Annual
Conversion of accrued expenses into common stock	`ConversionOfAccruedExpensesIntoCommonStock`	$126.00K	USD	Annual
Conversion of accrued expenses into common stock	`ConversionOfAccruedExpensesIntoCommonStock`	$207.00K	USD	Annual
Payment of debt issuance costs via warrants and common stock	`PaymentOfDebtIssuanceCostsViaWarrantsAndCommonStock`	$522.00K	USD	Annual
Payment of debt issuance costs via warrants and common stock	`PaymentOfDebtIssuanceCostsViaWarrantsAndCommonStock`	-	USD	Annual
Conversion of convertible debt into common stock	`ConversionOfConvertibleDebtIntoCommonStock`	-	USD	Annual
Conversion of convertible debt into common stock	`ConversionOfConvertibleDebtIntoCommonStock`	$893.00K	USD	Annual
Repayment of debt via issuance of common stock and warrants	`RepaymentOfDebtViaIssuanceOfCommonStockAndWarrants`	$1.70M	USD	Annual
Repayment of debt via issuance of common stock and warrants	`RepaymentOfDebtViaIssuanceOfCommonStockAndWarrants`	-	USD	Annual
Issuance of common stock as board compensation	`IssuanceOfCommonStockAsBoardCompensation`	$355.00K	USD	Annual
Issuance of common stock as board compensation	`IssuanceOfCommonStockAsBoardCompensation`	$463.00K	USD	Annual
Deemed dividends in the form of warrants to purchase common stock.	`DeemedDividendsInFormOfWarrantsToPurchaseCommonStock.`	-	USD	Annual
Deemed dividends in the form of warrants to purchase common stock.	`DeemedDividendsInFormOfWarrantsToPurchaseCommonStock.`	$537.00K	USD	Annual
Deemed dividends on preferred stock	`DeemedDividendsOnPreferredStock`	-	USD	Annual
Deemed dividends on preferred stock	`DeemedDividendsOnPreferredStock`	$3.15M	USD	Annual

Stockholders Equity 18 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance, Amount	`StockholdersEquity`	$-107.00K	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$-4.46M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$1.13M	USD	Point-in-time
Deemed dividends on beneficial conversion feature of preferred stock	`DeemedDividendsOnBeneficialConversionFeatureOfPreferredStock`	$-3.15M	USD	Annual
Issuance of common stock and warrants, Amount	`IssuanceOfCommonStockAndWarrants`	$3.37M	USD	Annual
Issuance of common stock, Amount	`IssuanceOfCommonStockAmount`	$162.00K	USD	Annual
Issuance of warrants	`AdjustmentsToAdditionalPaidInCapitalWarrantIssued`	$372.00K	USD	Annual
Issuance of stock options	`IssuanceOfStockOptions`	$61.00K	USD	Annual
Exercise of warrants/options, Amount	`ExerciseOfWarrantsoptionsAmount`	$96.00K	USD	Annual
Exercise of warrants/options, Amount	`ExerciseOfWarrantsoptionsAmount`	$3.10M	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$886.00K	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$824.00K	USD	Annual
Conversion of debts into common stock, Amount	`ConversionOfDebtsIntoCommonStockAmount`	$893.00K	USD	Annual
Net Loss	`NetIncomeLoss`	$-7.21M	USD	Annual
Net Loss	`NetIncomeLoss`	$-9.88M	USD	Annual
Ending Balance, Amount	`StockholdersEquity`	$-107.00K	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$-4.46M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$1.13M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.